The investigation of the tolerability and the cost, due to the drug change to novel oral anticoagurants (rivaroxaban) from warfarin in patients with nonvalvular atrial fibrillation in the perioperative period

The investigation of the tolerability and the cost, due to the drug change to novel oral anticoagurants (rivaroxaban) from warfarin in patients with nonvalvular atrial fibrillation in the perioperative period - The investigation of the tolerability and the cost, due to the drug change to novel oral anticoagurants (rivaroxaban) from warfarin in patients with nonvalvular atrial fibrillation in the perioperative period

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011103

Enrollment

Registered

2013-07-03

Start date

2013-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nonvalvular Atrial Fibrillation

Interventions

Xarelto is administered to patients at the dose of 15mg/day.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)The patients with nonvalvular atrial fibrillation who are scheduled to undergo surgery recommended to use Heparin 2)Patients who received sufficient explanation before participation in this study, understood it and gave written consent based on their free will

Exclusion criteria

Exclusion criteria: 1)The patients with contraindication of Xarelto 2)The patients who are not allowed to participate in the trial by the principal investigator

Design outcomes

Primary

Measure	Time frame
1)Inpatient days 2)In-hospital medical expense (including outpatient therapy)	—

Secondary

Measure	Time frame
Tolerability (existence or nonexistence of hemorrhage and orischemic events)	—

Countries

Japan

Contacts

Public ContactTakahisa YAMADA

Osaka General Medical Center Division of Cardiology

kenkyusien@gh.opho.jp06-6692-1201

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026